Literature DB >> 24246003

Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases.

Ronald M van Dam1, Toine M Lodewick, Maartje A J van den Broek, Mechteld C de Jong, Jan Willem Greve, Rob L H Jansen, Marc H A Bemelmans, Ulf P Neumann, Steven W M Olde Damink, Cornelis H C Dejong.   

Abstract

BACKGROUND: Currently, resection criteria for colorectal cancer liver metastases (CRCLM) are only limited by remnant liver function. Morbidity and survival after a partial hepatectomy with limited or extended indication criteria were compared. METHODS/
DESIGN: Between 1991 and 2010, patients undergoing a liver resection for CRCLM with limited (n = 169) or extended indication criteria (n = 129) were retrospectively identified in a prospectively collected single-centre database. Limited indication criteria were defined as less than three unilateral, not centrally located liver metastases in the absence of extra hepatic metastases. The extended criteria were only limited by predicted remnant liver volume and patients fitness. Data on co-morbidity, resection margin, short- and long-term morbidity, disease-free (DFS) and overall survival were compared.
RESULTS: Patients with limited indications had less major complications (19.5% vs. 33.1%, P < 0.01), longer overall survival of 68.8 months [confidence interval (CI) 46.5-91.1] vs. 41.4 months (CI 33.4-49.0, P ≤ 0.001) and longer median DFS of 22.0 months [confidence interval (CI) 15.8-28.2] vs 10.2 months (CI 8.4-11.9, P < 0.001) compared with the extended indication group. Cure rates, defined as 10-year DFS, were 35.5% and 15.8%, respectively. Fewer patients in the extended indication group underwent an R0 resection (92.9% vs. 77.5%, P < 0.001). Only 17% of all R1 resected patients had recurrences at the transection plane.
CONCLUSION: A partial hepatectomy for CRCLM with extended indications seems justified but is associated with higher complication rates, earlier recurrence and lower overall survival compared with limited indications. However, the median 5-year survival was substantial and a cure was achieved in 15.8% of patients.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2013        PMID: 24246003      PMCID: PMC4048077          DOI: 10.1111/hpb.12181

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  41 in total

1.  Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).

Authors:  T Ruers; C Punt; F Van Coevorden; J P E N Pierie; I Borel-Rinkes; J A Ledermann; G Poston; W Bechstein; M A Lentz; M Mauer; E Van Cutsem; M P Lutz; B Nordlinger
Journal:  Ann Oncol       Date:  2012-03-19       Impact factor: 32.976

2.  Split decision.

Authors:  U P Neumann; C H C Dejong
Journal:  Br J Surg       Date:  2013-02       Impact factor: 6.939

Review 3.  Surgical therapy of hepatic colorectal metastasis.

Authors:  Y Fong
Journal:  CA Cancer J Clin       Date:  1999 Jul-Aug       Impact factor: 508.702

4.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Authors:  Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

5.  Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors.

Authors:  R Adam; A Laurent; D Azoulay; D Castaing; H Bismuth
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

6.  Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.

Authors:  M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen
Journal:  Eur Radiol       Date:  2008-11-07       Impact factor: 5.315

7.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Authors:  Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne
Journal:  Lancet Oncol       Date:  2009-11-26       Impact factor: 41.316

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 9.  Expanding criteria for resectability of colorectal liver metastases.

Authors:  Timothy M Pawlik; Richard D Schulick; Michael A Choti
Journal:  Oncologist       Date:  2008-01

10.  XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

Authors:  J Cassidy; S Clarke; E Díaz-Rubio; W Scheithauer; A Figer; R Wong; S Koski; K Rittweger; F Gilberg; L Saltz
Journal:  Br J Cancer       Date:  2011-06-14       Impact factor: 7.640

View more
  16 in total

1.  Effect of Age on Liver Function in Patients Undergoing Partial Hepatectomy.

Authors:  T M Lodewick; P H Alizai; R M van Dam; A A J Roeth; M Schmeding; C Heidenhain; A Andert; N Gassler; C H C Dejong; U P Neumann
Journal:  Dig Surg       Date:  2017-02-15       Impact factor: 2.588

2.  Effects of postoperative morbidity on long-term outcome following surgery for colorectal liver metastases.

Authors:  T M Lodewick; M C de Jong; R M van Dam; M H A Bemelmans; U P Neumann; S W M Olde Damink; C H C Dejong
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

3.  R1 Resection for Colorectal Liver Metastases: a Survey Questioning Surgeons about Its Incidence, Clinical Impact, and Management.

Authors:  Luca Viganò; Guido Costa; Matteo Maria Cimino; Fabio Procopio; Matteo Donadon; Daniele Del Fabbro; Jacques Belghiti; Norihiro Kokudo; Masatoshi Makuuchi; Jean-Nicolas Vauthey; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2018-06-08       Impact factor: 3.452

4.  Validation of the peak bilirubin criterion for outcome after partial hepatectomy.

Authors:  Kim M C van Mierlo; Toine M Lodewick; Dipok K Dhar; Victor van Woerden; Ralph Kurstjens; Frank G Schaap; Ronald M van Dam; Soumil Vyas; Massimo Malagó; Cornelis H C Dejong; Steven W M Olde Damink
Journal:  HPB (Oxford)       Date:  2016-07-02       Impact factor: 3.647

5.  Fast and accurate liver volumetry prior to hepatectomy.

Authors:  Toine M Lodewick; Carsten W K P Arnoldussen; Max J Lahaye; Kim M C van Mierlo; Ulf P Neumann; Regina G Beets-Tan; Cornelis H C Dejong; Ronald M van Dam
Journal:  HPB (Oxford)       Date:  2016-07-02       Impact factor: 3.647

6.  Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?

Authors:  Toine M Lodewick; Thiemo J A van Nijnatten; Ronald M van Dam; Kim van Mierlo; Simon A W G Dello; Ulf P Neumann; Steven W M Olde Damink; Cornelis H C Dejong
Journal:  HPB (Oxford)       Date:  2014-12-16       Impact factor: 3.647

Review 7.  Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases.

Authors:  Valerio Lucidi; Alain Hendlisz; Jean-Luc Van Laethem; Vincent Donckier
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

Review 8.  Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes.

Authors:  Olga Golubnitschaja; Krishna Chander Sridhar
Journal:  Clin Exp Metastasis       Date:  2016-08-19       Impact factor: 5.150

Review 9.  Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.

Authors:  Rafif E Mattar; Faisal Al-Alem; Eve Simoneau; Mazen Hassanain
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern.

Authors:  Sébastien Tabariès; Matthew G Annis; Anthoula Lazaris; Stephanie K Petrillo; Jennifer Huxham; Amri Abdellatif; Vincent Palmieri; Jaclyn Chabot; Radia M Johnson; Steven Van Laere; Cornelis Verhoef; Yasmina Hachem; Sara Yumeen; Nicholas Meti; Atilla Omeroglu; Gulbeyaz Altinel; Zu-Hua Gao; Alan S L Yu; Dirk J Grünhagen; Peter Vermeulen; Peter Metrakos; Peter M Siegel
Journal:  Commun Biol       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.